Literature DB >> 12883204

Increased levels of syndecan-1 in serum during acute graft-versus-host disease.

Carina Seidel1, Olle Ringdén, Mats Remberger.   

Abstract

Acute graft-versus-host disease (GVHD) may affect several organs. Syndecan-1 is a heparan sulfate proteoglycan that can be shed from the surface of most epithelial cells (skin, liver, and gut among others), which are target organs for GVHD. Syndecan-1 was measured in serum samples from 60 patients after allogeneic stem-cell transplantation and was related to the degree of GVHD. Syndecan-1 levels increased in patients who developed acute GVHD but not in patients without GVHD. The difference between groups was significant 3 to 10 weeks after transplantation. The peak level of syndecan-1 in serum correlated with the degree of acute GVHD (r=0.46, P<0.001). Combined, the peak levels of syndecan-1 and soluble interleukin-2 receptor detected patients with acute GVHD (sensitivity 82%, specificity 89%). This study shows that syndecan-1 levels are increased during acute GVHD. Syndecan-1 may be a marker for acute GVHD, especially if combined with determination of soluble interleukin-2 receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883204     DOI: 10.1097/01.TP.0000074316.76104.A5

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

Review 1.  Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality.

Authors:  John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 2.  Soluble syndecans: biomarkers for diseases and therapeutic options.

Authors:  Jessica Bertrand; Miriam Bollmann
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

Review 3.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

Review 4.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

5.  Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5.

Authors:  Kazutaka Hayashida; Philip D Stahl; Pyong Woo Park
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

Review 6.  Plasma biomarkers in graft-versus-host disease: a new era?

Authors:  Sophie Paczesny; John E Levine; Thomas M Braun; James L M Ferrara
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

7.  Syndecan-1 Shedding Inhibition to Protect Against Ischemic Acute Kidney Injury Through HGF Target Signaling Pathway.

Authors:  Zhihui Lu; Nana Song; Bo Shen; XiaLian Xu; Yi Fang; Yiqin Shi; Yichun Ning; Jiachang Hu; Yan Dai; Xiaoqiang Ding; Jianzhou Zou; Jie Teng
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

8.  Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines.

Authors:  Kazutaka Hayashida; William C Parks; Pyong Woo Park
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

9.  Syndecan-1 is an in vivo suppressor of Gram-positive toxic shock.

Authors:  Kazutaka Hayashida; Ye Chen; Allison H Bartlett; Pyong Woo Park
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

10.  A biomarker panel for acute graft-versus-host disease.

Authors:  Sophie Paczesny; Oleg I Krijanovski; Thomas M Braun; Sung W Choi; Shawn G Clouthier; Rork Kuick; David E Misek; Kenneth R Cooke; Carrie L Kitko; Angela Weyand; Daniel Bickley; Dawn Jones; Joel Whitfield; Pavan Reddy; John E Levine; Samir M Hanash; James L M Ferrara
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.